Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.

Goudra, Basavana et al.·Pharmaceuticals (Basel·2024·
RPEP-082852024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.
Published In:
Pharmaceuticals (Basel, Switzerland), 18(1) (2024)
Database ID:
RPEP-08285

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-08285·https://rethinkpeptides.com/research/RPEP-08285

APA

Goudra, Basavana; Merli, Geno J; Green, Michael. (2024). Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.. Pharmaceuticals (Basel, Switzerland), 18(1). https://doi.org/10.3390/ph18010004

MLA

Goudra, Basavana, et al. "Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.." Pharmaceuticals (Basel, 2024. https://doi.org/10.3390/ph18010004

RethinkPeptides

RethinkPeptides Research Database. "Glucose-Lowering Agents Developed in the Last Two Decades an..." RPEP-08285. Retrieved from https://rethinkpeptides.com/research/goudra-2024-glucoselowering-agents-developed-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.